SABCS

SABCS: AZ writes the 'next chapter' in Enhertu's saga with head-to-head win versus Roche's Kadcyla
SABCS: AZ writes the 'next chapter' in Enhertu's saga with head-to-head win versus Roche's Kadcyla
Fierce Pharma
SABCS
AstraZeneca
Enhertu
breast cancer
Daiichi Sankyo
Roche
Kadcyla
Flag link:
SABCS: Novartis touts Kisqali's 5-year breast cancer survival, advantage over Pfizer's Ibrance
SABCS: Novartis touts Kisqali's 5-year breast cancer survival, advantage over Pfizer's Ibrance
Fierce Pharma
Novartis
Kisqali
breast cancer
SABCS
Flag link:
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer
Pharmaceutical Business Review
Roche
Perjeta
Herceptin
HER2+ breast cancer
SABCS
breast cancer
Flag link:
SABCS: Merck's Keytruda notches win in triple-negative breast cancer as Roche's Tecentriq falls short
SABCS: Merck's Keytruda notches win in triple-negative breast cancer as Roche's Tecentriq falls short
Fierce Pharma
Merck
Ketyruda
Roche
Tecentriq
immuno-oncology
SABCS
triple-negative breast cancer
Flag link:
SABCS: Roche's Perjeta builds case as add-on to Herceptin with new analysis
SABCS: Roche's Perjeta builds case as add-on to Herceptin with new analysis
Fierce Pharma
Roche
breast cancer
Herceptin
Perjeta
biosimilars
SABCS
Flag link:
SABCS: Seattle Genetics hails 'stunning' tucatinib breast cancer data
SABCS: Seattle Genetics hails 'stunning' tucatinib breast cancer data
Fierce Biotech
Seattle Genetics
breast cancer
tucatinib
HER2+ breast cancer
SABCS
Flag link:
SABCS 2019 – Astrazeneca and Daiichi join the Her2 resistance
SABCS 2019 – Astrazeneca and Daiichi join the Her2 resistance
EP Vantage
breast cancer
AstraZeneca
Daiichi Sankyo
SABCS
trastuzumab deruxtecan
Flag link: